These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 31734103)

  • 1. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.
    Krauss GL; Klein P; Brandt C; Lee SK; Milanov I; Milovanovic M; Steinhoff BJ; Kamin M
    Lancet Neurol; 2020 Jan; 19(1):38-48. PubMed ID: 31734103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures.
    Chung SS; French JA; Kowalski J; Krauss GL; Lee SK; Maciejowski M; Rosenfeld WE; Sperling MR; Mizne S; Kamin M
    Neurology; 2020 Jun; 94(22):e2311-e2322. PubMed ID: 32409485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cenobamate add-on therapy for drug-resistant focal epilepsy.
    Brigo F; Lattanzi S
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014941. PubMed ID: 39087564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study.
    Rosenfeld WE; Nisman A; Ferrari L
    Epilepsy Res; 2021 May; 172():106592. PubMed ID: 33662894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
    French JA; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; Curatolo P; de Vries PJ; Dlugos DJ; Berkowitz N; Voi M; Peyrard S; Pelov D; Franz DN
    Lancet; 2016 Oct; 388(10056):2153-2163. PubMed ID: 27613521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cenobamate: A New Adjunctive Agent for Drug-Resistant Focal Onset Epilepsy.
    Buckley CT; Waters OR; DeMaagd G
    Ann Pharmacother; 2021 Mar; 55(3):318-329. PubMed ID: 32623899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
    Knight EMP; Amin S; Bahi-Buisson N; Benke TA; Cross JH; Demarest ST; Olson HE; Specchio N; Fleming TR; Aimetti AA; Gasior M; Devinsky O;
    Lancet Neurol; 2022 May; 21(5):417-427. PubMed ID: 35429480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.
    Van Paesschen W; Hirsch E; Johnson M; Falter U; von Rosenstiel P
    Epilepsia; 2013 Jan; 54(1):89-97. PubMed ID: 22813235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial.
    Inoue Y; Tiamkao S; Zhou D; Cabral-Lim L; Lim KS; Lim SH; Tsai JJ; Moseley B; Wang L; Sun W; Hayakawa Y; Sasamoto H; Sano T; McClung C; Bass A
    Epilepsia Open; 2024 Jun; 9(3):1007-1020. PubMed ID: 38576178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: A meta-analysis.
    Zhang L; Wang J; Wang C
    Acta Neurol Scand; 2021 Jul; 144(1):58-66. PubMed ID: 33788253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study.
    Varughese RT; Shah YD; Karkare S; Kothare SV
    Epilepsy Behav; 2022 May; 130():108679. PubMed ID: 35381496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study.
    Sperling MR; Klein P; Aboumatar S; Gelfand M; Halford JJ; Krauss GL; Rosenfeld WE; Vossler DG; Wechsler R; Borchert L; Kamin M
    Epilepsia; 2020 Jun; 61(6):1099-1108. PubMed ID: 32396252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study.
    Sperling MR; Abou-Khalil B; Aboumatar S; Bhatia P; Biton V; Klein P; Krauss GL; Vossler DG; Wechsler R; Ferrari L; Grall M; Rosenfeld WE
    Epilepsia; 2021 Dec; 62(12):3005-3015. PubMed ID: 34633084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients: Post Hoc Analysis of a Phase III, Multicenter, Open-Label Study.
    O'Dwyer R; Stern S; Wade CT; Guggilam A; Rosenfeld WE
    Drugs Aging; 2024 Mar; 41(3):251-260. PubMed ID: 38446341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis.
    Lattanzi S; Trinka E; Zaccara G; Striano P; Del Giovane C; Silvestrini M; Brigo F
    CNS Drugs; 2020 Nov; 34(11):1105-1120. PubMed ID: 32851590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
    Steinhoff BJ; Patten A; Williams B; Malhotra M
    Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.